The study of 1 patient death in the Brazil trial of AstraZeneta's new crown vaccine has not been called off

Recently, according to foreign media reports, in AstraZeneta's global COVID-19 vaccine phase III study, there was a case of subject death, affected by this news, AstraZeneta shares fell slightly.
few details about the death of one volunteer in the new crown vaccine trial.
the death was Brazilian, according to CNBC.
, it is not clear whether AstraZeneta's COVID-19 vaccine, AZD1222, is a fatal factor in the patient.
despite the deaths, the third phase of the trial in Brazil is now expected to continue.
AstraZeneta and Oxford University, the company's research partner in vaccine trials, did not comment on the deaths.
assalis spokesman said the practice complied with "medical confidentiality and clinical trials," CNBC reported.
spokesman added that "important medical events in the trial will be carefully assessed by the trial researchers," adding: "Based on the current assessment, there are no concerns about ongoing research."
"It is worth noting that Oxford University seems to have the same view.
a spokesman for The University of Oxford also told CNBC that after assessing deaths in Brazil, "there are no concerns about the safety of the current clinical trials of vaccines."
in addition to Brazilian regulators, independent reviewers have recommended that vaccine trials continue," Oxford spokesman Alexander Buxton told CNBC.
" So far, the global outbreak of new crown pneumonia continues to spread, with the top two countries in the world being the United States and India, and Brazil reporting the third-highest number of COVID-19 infections in the world.
the Brazilian government has reported more than 5.2 million new cases of coronary pneumonia, with 154,837 deaths, according to Johns Hopkins.
hours after news broke that the Brazilian trial had resulted in the death of a patient, there were other media reports that the FDA might decide to cancel AstraZeneta's ongoing phase III vaccine study for coronary pneumonia in the United States.
trial has been suspended in the US since September after reports of transverse spinal corditis, a severe spinal cord disease, in patients receiving vaccine candidate AZD1222 in the UK.
but the woman did not eventually die and was treated at the hospital and discharged home.
a brief survey by the UK's Medicines and Health Products Regulatory Agency (MHRA) that found there was insufficient evidence that the disease was directly caused by the vaccine, the trial was allowed to continue in the UK.
AstraZeneta's COVID-19 candidate vaccine, AZD1222, is a weakened adenovirus based on a viral vector, developed by the Jenner Institute at Oxford University and in collaboration with the Oxford Vaccine Team, using a viral vector based on a weak version of the adenovirus, which is loaded with genetic material from the SARS-CoV-2 spike protein.
, a surface prickly protein is produced, which triggers an attack on the immune system if the patient is later infected with the new coronavirus.
July, the company released positive data from the vaccine's Phase I trial, showing that AZD1222 produces both meso-antibodies in patients and immune T cells that cause the COVID-19 virus.
, AstraZeneta is also testing the AZD1222 vaccine in India and South Africa.
If the vaccine is eventually regulatoryly assessed and successfully produced, AstraZeneta plans to produce up to 2 billion doses of the vaccine, of which 400 million are expected to be used in the United States and the United Kingdom and 1 billion in low- and middle-income countries.